Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility. Its first approved product, MYQORZO (aficamten), is aimed at obstructive hypertrophic cardiomyopathy (oHCM), and the company is using that launch to transition from a development-stage organization into a commercial cardiology franchise. Beyond MYQORZO, Cytokinetics is developing additional cardiac muscle modulators for non-obstructive HCM, HFpEF, and heart failure with reduced ejection fraction. The business is centered on a narrow set of cardiologists, specialty centers, and payors that can support adoption of a highly targeted cardiovascular therapy.
−683,9 %
−891,6 %
+376,6 %
4.53
4.53
| % | |
|---|---|
| Commercial cardiology product | 10% MYQORZO, the company’s first approved medicine, for symptomatic obstructive hypertrophic cardiomyopathy. |
| Licensed international rights | 35% Out-licensing and collaboration rights for aficamten in markets such as Japan and China. |
| Milestone and collaboration revenue | 55% Up-front, clinical, regulatory, and commercial milestone payments plus R&D reimbursements from partners. |
| Pipeline therapeutics | 0% Earlier-stage drug candidates including ulacamten and omecamtiv mecarbil. |
Cytokinetics sells primarily to a concentrated group of cardiologists who diagnose and initiate treatment for...
Specialist physicians who diagnose and initiate treatment for obstructive HCM and are the main prescribers for MYQORZO.
Academic and specialty centers that treat complex HCM cases and can accelerate adoption of a new cardiology therapy.
Government and commercial reimbursement decision-makers that determine formulary access and patient affordability.
The end patients who receive the therapy and drive demand once diagnosis, coverage, and prescribing align.
Bayer and Sanofi commercialize or support aficamten in selected markets and generate milestone and royalty economics.
Cytokinetics is headquartered in the United States and has built its initial commercial infrastructure there for...
Cytokinetics’ strategy is to build a specialty cardiology franchise around MYQORZO and then extend that franchise with...
The first approved product is the anchor for the company’s transition to a commercial business and the main source of future product revenue.
A second direct-launch geography can broaden the addressable market and diversify revenue beyond the U.S.
Licensing in China and Japan can accelerate market entry while reducing the need for a fully owned commercial buildout.
Additional assets are needed to sustain the franchise and reduce dependence on a single product.
Cytokinetics faces the classic risks of a late-stage and newly commercial biopharmaceutical company: regulatory...
Drug candidates and label expansions require successful FDA and foreign regulatory review, which can be delayed or denied based on safety, efficacy, or manufacturing concerns.
Even approved therapies may not gain traction if prescribers prefer existing options or if safety, convenience, or reimbursement are unfavorable.
Access depends on PBM and insurer coverage, and rebates or delayed formulary placement can reduce realized economics.
The company has historically used external capital and may need additional funding if product revenue ramps slowly or development spending remains elevated.
International monetization relies on Bayer and Sanofi for development, launch, and commercialization in selected markets.
CYTK · Pharmaceutical Preparations
Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility.
BOOZT.ST · Consumer Discretionary
BUFAB.ST · Industrials
APOTEA.ST · Consumer Staples
SAVE.ST · Financials
METSO.HE · Farm & Heavy Construction Machinery
: 28.4.2026